SLShaojian Lin

Shaojian Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shaojian Lin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Da-Peng Wang

    Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Debing Tong

    Department of Cardiology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China

    1 shared publication
  • Hanbing Shang

    Department of Neurosurgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China

    1 shared publication
  • Hao Tang

    Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    1 shared publication
  • Hong Yao

    Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication
  • Li Xue

    Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas

    by Yijun Cheng, Dapeng Wang, Hao Tang, Debing Tong, Weiguo Zhao, Shaojian Lin, Hong Yao, Wenwen Lv, Xun Zhang, Li Xue, et al.

    Several subtypes of pituitary neuroendocrine tumors (PitNETs), such as acromegaly and Cushing’s disease, can result in hypertension. However, whether prolactinoma is associated with this complication remains unknown. Moreover, the effect of treatment with surgery or drugs on blood pressure (BP) is unknown. Herein, a retrospective study reviewed 162 patients with prolactinoma who underwent transsphenoidal surgery between January 2005 and December 2022. BP measurements were performed 1 day before and 5 days after surgery. Accordingly, patients’ medical characteristics were recorded. In addition, in situ rat and xenograft nude-mice prolactinoma models have been used to mimic prolactinoma. In vivo BP and serum prolactin (PRL) levels were measured after cabergoline (CAB) administration in both rats and mice. Our data suggest that surgery can effectively decrease BP in prolactinoma patients with or without hypertension. The BP-lowering effect was significantly associated with several variables, including age, sex, disease duration, tumor size, invasion, dopamine agonists (DAs)-resistance, recurrence, and preoperative PRL levels. Moreover, in situ and xenograft prolactinomas induced BP elevation, which was alleviated by CAB treatment without and with a statistical difference in rats and mice, respectively. Thus, surgery or CAB can decrease BP in prolactinoma, indicating that pre- and postoperative BP management becomes essential.